The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate.
about
The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnoverThe Vpr protein from HIV-1: distinct roles along the viral life cyclePlunder and stowaways: incorporation of cellular proteins by enveloped virusesHuman immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylasesViral mutation ratesHIV-1 Vif, APOBEC, and intrinsic immunityDDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrestLentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycleHIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integrationdUTPase: the frequently overlooked enzyme encoded by many retrovirusesHIV-1 reverse transcriptionMechanisms of viral mutationInfluence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies.3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase.Characterization of the molecular determinants of primary HIV-1 Vpr proteins: impact of the Q65R and R77Q substitutions on Vpr functions.HIV-1 Vpr stimulates NF-κB and AP-1 signaling by activating TAK1.Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.In vivo analysis of human T-cell leukemia virus type 1 reverse transcription accuracy.Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.Vpr-host interactions during HIV-1 viral life cycle.Human immunodeficiency virus type 1 central DNA flap: dynamic terminal product of plus-strand displacement dna synthesis catalyzed by reverse transcriptase assisted by nucleocapsid protein.The functions of the HIV1 protein Vpr and its action through the DCAF1.DDB1.Cullin4 ubiquitin ligase.X4 and R5 HIV-1 have distinct post-entry requirements for uracil DNA glycosylase during infection of primary cells.Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.Protein kinase A phosphorylation activates Vpr-induced cell cycle arrest during human immunodeficiency virus type 1 infection.The human antiviral factor TRIM11 is under the regulation of HIV-1 Vpr.Exposed hydrophobic residues in human immunodeficiency virus type 1 Vpr helix-1 are important for cell cycle arrest and cell deathHuman immunodeficiency virus reverse transcriptase displays dramatically higher fidelity under physiological magnesium conditions in vitro.Recruitment of the nuclear form of uracil DNA glycosylase into virus particles participates in the full infectivity of HIV-1.HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation.Using death to one's advantage: HIV modulation of apoptosis.Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells.Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.Retroviral vectors for analysis of viral mutagenesis and recombination.Functional genomics in HIV-1 virus replication: protein-protein interactions as a basis for recruiting the host cell machinery for viral propagation.Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA.Potential roles of cellular proteins in HIV-1.Abundant non-canonical dUTP found in primary human macrophages drives its frequent incorporation by HIV-1 reverse transcriptase.
P2860
Q21134793-95013DFA-3A6E-42CF-B6B7-F9153B788A82Q21245211-59C03486-B628-4CD8-B774-84AD996897CFQ24524170-3BF8AEB7-BE0C-42CA-BB38-7D4221132D74Q24530147-CE700C15-E1E8-422F-9281-5A0A3BD047FBQ24611162-F0D93DF6-C5B9-48FC-A881-B4DFD4F7573EQ24647833-2311A2ED-7B44-48F7-9E6A-4D4EBE414BF1Q24671784-3EEE5FA4-7705-4C8E-A19D-11F32B593A40Q24680705-42C0B010-E13D-4D90-9567-C95A6BBD4424Q24681112-BBACC1C0-C332-4274-AB36-8C9DC34F95D0Q24684279-B108683F-1E83-49CC-88C1-86BDB380D89DQ26799724-117D98B0-8170-4739-9F3E-82BA676BE5A2Q27023387-BC26CFD8-1A1E-4040-8A3B-16A761B15F72Q28067235-B7B63E37-5719-44FE-A5FB-2E0F34B060C7Q30453160-B50D8A27-2D0B-4810-B4C9-F0F1AFCAAE01Q30453467-A664C359-02E4-4FE9-8EA6-38612B5DB1E9Q33290831-4ECE3D38-5AEB-48FC-B022-BC6C151D21CBQ33511235-D57D1D12-F1EC-41EC-956D-74ECB77DEFC7Q33756614-0745B9DF-6B3C-4293-A1F4-479E4387AE9CQ33786404-7E8F436F-5B73-41CA-935E-4BD9C6E8CC52Q33811519-B3808518-E72A-4EB6-AB44-B341E90BE6C3Q33815187-74E7A803-2C4A-48BA-BA15-30C0DC1E3C15Q33828332-723B16B3-1372-49AD-8019-CCCBCC2E7627Q33838354-DDD4C609-5D56-4FEC-9468-8F2D3DCBE315Q33891972-39A24C1E-D3F6-4C17-8C5E-2ADF5029D6FCQ33897859-30CA80C7-B0B4-4412-A1B8-B3FB606D00E8Q33987492-DB3232E8-C4E0-4667-9F6F-80C66F22B2F8Q33990739-21BDB2D1-DDD4-4D10-90D3-E01DBCDD8832Q34020546-6700BD47-20DB-412E-9056-111DC86FF605Q34031619-AA7EA516-7430-436B-BD8F-FAFCD7065D21Q34057801-EAF09651-C415-4173-84FC-680C6624C0A2Q34101635-78529D4D-7EC4-46FC-A85B-88D1FEB59947Q34140089-A5CF506A-3F75-4439-A471-71973ECBD097Q34173884-573E57DA-0FD9-41AF-B008-B3B78217F9B7Q34263217-C0813F0C-C739-4C6E-B7F1-9D2402242552Q34301892-8C7D1265-88A6-4E5D-9F55-86BE83D372DBQ34303615-98D6FA94-CDF7-4B0F-9D3A-C929420EACAFQ34352239-F1DA5C77-1BCD-4511-9B53-9035596F8A37Q34733579-F4278409-5D09-47CB-810E-535BE8E56E84Q34985857-047DFA01-0570-4FE2-B52E-6EF6C28D4CFAQ35107515-24C7B23E-5D64-444E-A37F-1637E95315E2
P2860
The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The interaction of vpr with ur ...... type 1 In vivo mutation rate.
@ast
The interaction of vpr with ur ...... type 1 In vivo mutation rate.
@en
type
label
The interaction of vpr with ur ...... type 1 In vivo mutation rate.
@ast
The interaction of vpr with ur ...... type 1 In vivo mutation rate.
@en
prefLabel
The interaction of vpr with ur ...... type 1 In vivo mutation rate.
@ast
The interaction of vpr with ur ...... type 1 In vivo mutation rate.
@en
P2093
P2860
P1433
P1476
The interaction of vpr with ur ...... type 1 In vivo mutation rate.
@en
P2093
P2860
P304
P356
10.1128/JVI.74.15.7039-7047.2000
P577
2000-08-01T00:00:00Z